Last updated: 18 July 2019 at 3:49pm EST

Kevin M. Slawin Net Worth




The estimated Net Worth of Kevin M. Slawin is at least $7.02 million dollars as of 7 February 2017. Kevin Slawin owns over 30,000 units of Bellicum Pharmaceuticals Inc stock worth over $22,050 and over the last 10 years Kevin sold BLCM stock worth over $7,000,464.

Kevin Slawin BLCM stock SEC Form 4 insiders trading

Kevin has made over 16 trades of the Bellicum Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Kevin sold 30,000 units of BLCM stock worth $376,200 on 7 February 2017.

The largest trade Kevin's ever made was selling 67,000 units of Bellicum Pharmaceuticals Inc stock on 15 August 2016 worth over $1,293,770. On average, Kevin trades about 21,048 units every 27 days since 2014. As of 7 February 2017 Kevin still owns at least 294,982 units of Bellicum Pharmaceuticals Inc stock.

You can see the complete history of Kevin Slawin stock trades at the bottom of the page.



What's Kevin Slawin's mailing address?

Kevin's mailing address filed with the SEC is C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON, TX, 77030.

Insiders trading at Bellicum Pharmaceuticals Inc

Over the last 10 years, insiders at Bellicum Pharmaceuticals Inc have traded over $18,000,835 worth of Bellicum Pharmaceuticals Inc stock and bought 249,666 units worth $2,145,232 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli... et Jon P Stonehouse. On average, Bellicum Pharmaceuticals Inc executives and independent directors trade stock every 32 days with the average trade being worth of $2,494. The most recent stock trade was executed by James M Daly on 3 January 2023, trading 60,414 units of BLCM stock currently worth $4,516.



What does Bellicum Pharmaceuticals Inc do?

bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.



What does Bellicum Pharmaceuticals Inc's logo look like?

Bellicum Pharmaceuticals Inc logo

Complete history of Kevin Slawin stock trades at Bellicum Pharmaceuticals Inc

Date
#
Société
Initié
Trans.
Transaction
Actions Prix par action Prix ​​total Actions après Source
7 Feb 2017 Kevin M. Slawin
CMO et CTO
Vente 30,000 $12.54 $376,200
7 Feb 2017
294,982
15 Dec 2016 Kevin M. Slawin
CMO et CTO
Vente 30,000 $15.45 $463,500
15 Dec 2016
324,982
21 Sep 2016 Kevin M. Slawin
CMO et CTO
Vente 23,416 $20.12 $471,130
21 Sep 2016
354,982
16 Sep 2016 Kevin M. Slawin
CMO et CTO
Vente 4,584 $20.01 $91,726
16 Sep 2016
367,040
15 Aug 2016 Kevin M. Slawin
CMO et CTO
Vente 67,000 $19.31 $1,293,770
15 Aug 2016
368,982
15 Aug 2016 Kevin M. Slawin
CMO et CTO
Vente 67,000 $19.31 $1,293,770
15 Aug 2016
368,982
27 Jul 2016 Kevin M. Slawin
CMO et CTO
Vente 15,000 $15.00 $225,000
27 Jul 2016
399,982
27 Jul 2016 Kevin M. Slawin
CMO et CTO
Vente 15,000 $15.00 $225,000
27 Jul 2016
399,982
18 Jul 2016 Kevin M. Slawin
CMO et CTO
Vente 2,719 $13.99 $38,039
18 Jul 2016
134,206
18 Jul 2016 Kevin M. Slawin
CMO et CTO
Vente 2,719 $13.99 $38,039
18 Jul 2016
134,206
15 Jul 2016 Kevin M. Slawin
CMO et CTO
Vente 22,281 $13.72 $305,695
15 Jul 2016
136,925
15 Jul 2016 Kevin M. Slawin
CMO et CTO
Vente 22,281 $13.72 $305,695
15 Jul 2016
136,925
22 Apr 2016 Kevin M. Slawin
CMO et CTO
Vente 55,000 $11.43 $628,650
22 Apr 2016
414,982
22 Apr 2016 Kevin M. Slawin
CMO et CTO
Vente 55,000 $11.43 $628,650
22 Apr 2016
414,982
16 Nov 2015 Kevin M. Slawin
CMO et CTO
Vente 24,000 $20.65 $495,600
16 Nov 2015
398,066
15 Jul 2015 Kevin M. Slawin
CMO et CTO
Vente 6,000 $20.00 $120,000
15 Jul 2015
402,066


Bellicum Pharmaceuticals Inc executives and stock owners

Bellicum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: